Proteomics International Advances U.S. Commercialization with CAP Accreditation and New Mass Spec Lab
Proteomics International Laboratories Ltd (ASX: PIQ) has achieved a significant milestone in its U.S. commercialization efforts with the accreditation of its USA Reference Laboratory by the College of American Pathologists (CAP). This accreditation follows a rigorous inspection process and positions the laboratory among over 8,000 CAP-accredited facilities worldwide. It complements the laboratory’s existing Clinical Laboratory Improvement Amendment (CLIA) certification.
CAP accreditation is considered the gold standard for laboratory quality in the U.S., ensuring the highest level of care and reliability in clinical testing. The company has successfully set up a new mass spectrometry platform, which will play a key role in advancing the commercialization of its Promarker suite of diagnostic blood tests, including PromarkerEso for esophageal cancer. This platform boosts the laboratory's capabilities and paves the way for the launch of PromarkerEso in 2026. Proteomics International is also expanding its global reach and reinforcing its leadership in the field of precision diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Proteomics International Advances U.S. Commercialization with CAP Accreditation and New Mass Spec Lab
Proteomics International Laboratories Ltd (ASX: PIQ) has achieved a significant milestone in its U.S. commercialization efforts with the accreditation of its USA Reference Laboratory by the College of American Pathologists (CAP). This accreditation follows a rigorous inspection process and positions the laboratory among over 8,000 CAP-accredited facilities worldwide. It complements the laboratory’s existing Clinical Laboratory Improvement Amendment (CLIA) certification.
CAP accreditation is considered the gold standard for laboratory quality in the U.S., ensuring the highest level of care and reliability in clinical testing. The company has successfully set up a new mass spectrometry platform, which will play a key role in advancing the commercialization of its Promarker suite of diagnostic blood tests, including PromarkerEso for esophageal cancer. This platform boosts the laboratory's capabilities and paves the way for the launch of PromarkerEso in 2026. Proteomics International is also expanding its global reach and reinforcing its leadership in the field of precision diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au